Tradestie Institutional Equity Comparison Engine

MRNA vs NIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

NIO Overall Edge

NIO Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to NIO Inc. American depositary shares, each representing one Class A ordinary share (NIO) driven by superior Growth & Margin, Options & Structure while MRNA counters with relative strength in Valuation, Momentum & Technical. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus NIO at 48.5x Forward P/E and -3.3% operating margin (+69.1% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against NIO sits in BREAKDOWN (50th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MRNA
MRNA 23.0x vs NIO 48.5x Fwd P/E
Growth & Margin Winner NIO
Op Margin -80.8% vs -3.3% ยท YoY +29.2% vs +69.1%
Momentum & Technical Winner MRNA
1Y +706.5% vs -57.4% ยท 52W Pos 67% vs 0%
Options & Structure Winner NIO
CONSOLIDATION (52nd %ile IV) vs BREAKDOWN (50th %ile IV)
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
NIO NYSE
NIO Inc. American depositary shares, each representing one Class A ordinary share
Motor Vehicles & Passenger Car Bodies
$2.45
-7.89% 1D
Market Cap $6.3B
1M Return -25.98%
1Y Return -57.39%
Forward P/E 48.5x
Unified AI Score
43.9 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 71.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MRNA +706.45% NIO -57.39% Spread: +763.84 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period MRNA Revenue NIO Revenue MRNA Op. Margin NIO Op. Margin Margin Edge
FY2018 $140M $720M -306.0% -193.8% NIO
FY2019 $60M $1.12B -906.8% -141.6% NIO
FY2020 $800M $2.49B -95.0% -28.3% NIO
FY2021 $18.5B $5.67B 72.0% -12.4% MRNA
FY2022 $19.3B $7.14B 48.9% -31.7% MRNA
FY2023 $6.85B $7.83B -61.9% -40.7% NIO
FY2024 $3.24B $9.01B -121.9% -33.3% NIO
FY2025 $1.94B $12.5B -158.1% -16.0% NIO

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MRNA (5) vs NIO (5)
Institutional Metric MRNA NIO Criterion Row Winner
Market Capitalization Scale $80.7B $6.3B Larger Scale MRNA
Trailing P/E Ratio Valuation 23.0x 48.5x Lower Multiple MRNA
Forward P/E Ratio Valuation 23.0x 48.5x Lower Multiple MRNA
Revenue Growth (YoY) Growth +29.2% +69.1% Higher Growth NIO
Operating Margin (TTM) Profitability -80.8% -3.3% Higher Margin NIO
Net Profit Margin Profitability -110.5% -4.2% Higher Margin NIO
Return on Equity (ROE) Capital Efficiency -34.5% -45.3% Higher ROE MRNA
52-Week Range Position Momentum 67% ($22โ€“$281) 0% ($2โ€“$7) Stronger Trend MRNA
Beta / 30D Volatility Risk Regime 2.23ฮฒ ยท 78% Vol 1.31ฮฒ ยท 53% Vol Lower Realized Risk NIO
Unified Institutional Score Composite Signal 40.3 / 100 (SELL) 43.9 / 100 (HOLD) Higher Composite NIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MRNA vs NIO Buy Guide
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
NIO BREAKDOWN
152d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live NIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MRNA nor NIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.